Melanocortin system in cancer-related cachexia

J 2011

Melanocortin system in cancer-related cachexia

BIENERTOVÁ VAŠKŮ, Julie; Petr BIENERT; Dalibor VALÍK a Anna VAŠKŮ

Základní údaje

Originální název

Melanocortin system in cancer-related cachexia

Název česky

Melanokortinový systém v kachexii spojené s nádorovým onemocněním

Autoři

BIENERTOVÁ VAŠKŮ, Julie; Petr BIENERT; Dalibor VALÍK a Anna VAŠKŮ

Vydání

Central European Journal of Medicine, Warsaw, Versita, 2011, 1895-1058

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30202 Endocrinology and metabolism

Stát vydavatele

Polsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.312

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00052653

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.2478/s11536-011-0057-6

UT WoS

000293708800005

Klíčová slova česky

melanokortiny; agouti-related peptid; kachexie, nádorová onemocnění

Klíčová slova anglicky

melanocortins; agouti-related peptide; cachexia; cancer

Příznaky

Mezinárodní význam

Změněno: 5. 12. 2011 13:31, Mgr. Michal Petr

Anotace

ORIG CZ

V originále

The melanocortin system plays a pivotal role in the regulation of appetite and energy balance. It was recognized to play an important role in the development of cancer-related cachexia, a debilitating condition characterized by progressive body wasting associated with anorexia, increased resting energy expediture and loss of fat as well as lean body mass that cannot be simply prevented or treated by adequate nutritional support. The recent advances in understanding of mechanisms underlying cancer-related cachexia led to consequent recognition of the melanocortin system as an important potential therapeutic target. Several molecules have been made available for animal experiments, including those with oral bioavailability, that act at various checkpoints of the melanocortin system and that might confer singificant benefits for the patients suffering from cancer-related cachexia. The application of melanocortin 4 receptor antagonists/agouti-related peptide agonists has been however restricted to animal models and more pharmacological data will be necessary to progress to clinical trials on humans. Still, pharmacological targeting of the melanocortin system seem to represent an elegant and promising way of treatment of cancer-related cachexia.

Česky

Tato review poskytuje přehled o významu melanokortinové dráhy při vzniku nádorové kachexia a zabývá se také možnými důsledky pro léčbu pacienta s nádorovým onemocněním.

Citovat

BIENERTOVÁ VAŠKŮ, Julie; Petr BIENERT; Dalibor VALÍK a Anna VAŠKŮ. Melanocortin system in cancer-related cachexia. Central European Journal of Medicine. Warsaw: Versita, 2011, roč. 6, č. 5, s. 550-557. ISSN 1895-1058. Dostupné z: https://doi.org/10.2478/s11536-011-0057-6.

@article{945142,
   author = {Bienertová Vašků, Julie and Bienert, Petr and Valík, Dalibor and Vašků, Anna},
   article_location = {Warsaw},
   article_number = {5},
   doi = {https://doi.org/10.2478/s11536-011-0057-6},
   keywords = {melanocortins; agouti-related peptide; cachexia; cancer},
   language = {eng},
   issn = {1895-1058},
   journal = {Central European Journal of Medicine},
   title = {Melanocortin system in cancer-related cachexia},
   volume = {6},
   year = {2011}
}

TY  - JOUR
ID  - 945142
AU  - Bienertová Vašků, Julie - Bienert, Petr - Valík, Dalibor - Vašků, Anna
PY  - 2011
TI  - Melanocortin system in cancer-related cachexia
JF  - Central European Journal of Medicine
VL  - 6
IS  - 5
SP  - 550-557
EP  - 550-557
PB  - Versita
SN  - 18951058
KW  - melanocortins
KW  - agouti-related peptide
KW  - cachexia
KW  - cancer
N2  - The melanocortin system plays a pivotal role in the regulation of appetite and energy balance. It was recognized to play an important role in the development of cancer-related cachexia, a debilitating condition characterized by progressive body wasting associated with anorexia, increased resting energy expediture and loss of fat as well as lean body mass that cannot be simply prevented or treated by adequate nutritional support. The recent advances in understanding of mechanisms underlying cancer-related cachexia led to consequent recognition of the melanocortin system as an important potential therapeutic target. Several molecules have been made available for animal experiments, including those with oral bioavailability, that act at various checkpoints of the melanocortin system and that might confer singificant benefits for the patients suffering from cancer-related cachexia. The application of melanocortin 4 receptor antagonists/agouti-related peptide agonists has been however restricted to animal models and more pharmacological data will be necessary to progress to clinical trials on humans. Still, pharmacological targeting of the melanocortin system seem to represent an elegant and promising way of treatment of cancer-related cachexia.
ER  -

BIENERTOVÁ VAŠKŮ, Julie; Petr BIENERT; Dalibor VALÍK a Anna VAŠKŮ. Melanocortin system in cancer-related cachexia. \textit{Central European Journal of Medicine}. Warsaw: Versita, 2011, roč.~6, č.~5, s.~550-557. ISSN~1895-1058. Dostupné z: https://doi.org/10.2478/s11536-011-0057-6.

Přehled o publikaci